International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(18), С. 10262 - 10262
Опубликована: Сен. 6, 2022
Cladribine
(CLD)
treats
multiple
sclerosis
(MS)
by
selectively
and
transiently
depleting
B
T
cells
with
a
secondary
long-term
reconstruction
of
the
immune
system.
This
study
provides
evidence
CLD’s
immunomodulatory
role
in
peripheral
blood
mononuclear
(PBMCs)
harvested
from
40
patients
untreated
relapsing-remitting
MS
(RRMS)
exposed
to
CLD.
We
quantified
cytokine
secretion
PBMCs
isolated
density
gradient
centrifugation
Ficoll−Paque
using
xMAP
technology
on
FlexMap
3D
analyzer
highly
sensitive
multiplex
immunoassay
kit.
The
PBMC
secretory
profile
was
evaluated
without
CLD
exposure.
RRMS
for
≤12
months
had
significantly
higher
IL-4
but
lower
IFN-γ
TNF-α
after
>12
altered
inflammatory
ratios
toward
an
anti-inflammatory
increased
decreased
induced
nonsignificant
changes
IL-17
both
groups.
Our
findings
reaffirm
effect
that
induces
phenotype.
Therapeutic Advances in Neurological Disorders,
Год журнала:
2021,
Номер
14
Опубликована: Янв. 1, 2021
To
report
on
safety
and
effectiveness
of
subcutaneous
cladribine
(Litak®)
in
multiple
sclerosis
(MS)
patients.Litak®
was
offered
to
MS-patients
irrespective
disease
course.
Litak®
10
mg
administered
for
3-4
days
during
week
1.
Based
lymphocyte
count
at
4,
patients
received
another
0-3
doses
5.
A
second
course
11
months
later.
Follow-up
included
adverse
events,
relapses,
expanded
disability
status
scale
(EDSS),
9-hole-peg
Timed-25-foot-walking
tests,
no-evidence-of-disease-activity
(NEDA),
no-evidence-of-progression-or-active-disease
(NEPAD),
MRI,
cerebrospinal
fluid
(CSF)
neurofilament
light
chain
(NfL),
counts.In
all,
208
least
one
treatment.
Age
baseline
44
(17-72)
years
EDSS
0-8.5.
Cladribine
generally
well
tolerated.
One
myocardial
infarction,
breast
cancer,
three
severe
skin
reactions
occurred
without
long-term
sequelae.
Two
died
(one
pneumonia,
encephalitis).
Lymphopenia
grade
3
5%
4
0.5%.
In
94
out
116
pwMS
with
follow-up
(BaFU)
data
after
two
treatment
courses,
remained
stable
or
improved.
At
18
months,
64%
relapsing
MS
BaFU
(n
=
39)
had
NEDA.
19
62%
progressive
13)
NEPAD.
Of
n
13
whose
CSF-NfL
elevated,
77%
were
normalised
within
12
months.Litak®
Effectiveness
appeared
similar
tablets
encouraging
MS.
Our
suggest
may
be
safe
effective
their
stage.
Frontiers in Neurology,
Год журнала:
2024,
Номер
15
Опубликована: Апрель 10, 2024
Object
The
purpose
of
this
study
was
to
evaluate
the
risk
secondary
immune
thrombocytopenia
in
multiple
sclerosis
patients
treated
with
alemtuzumab
through
a
meta-analysis.
Methods
We
searched
databases
including
PubMed,
Web
Science,
OVID
and
EMBASE
for
studies
reporting
changes
platelet
levels
MS
from
their
inception
until
May
2023
performed
Information
data
were
screened
extracted
by
two
researchers.
inclusion
exclusion
criteria
established
according
PICOS
principle.
obtained
analyzed
using
R
software
meta
package
quality
assessment
conducted
Newcastle-Ottawa
Scale
(NOS).
causes
heterogeneity
subgroup
analysis
sensitivity
analysis.
Publication
bias
evaluated
funnel
plots
Egger
test.
Results
A
total
15
included,
encompassing
1,729
patients.
Meta-analysis
overall
ITP
included
yielded
pooled
rate
0.0243.
incidence
autoimmune
events
0.2589.
In
addition,
applied
regions
types.
results
showed
that
Europe
about
0.0207,
while
(AEs)
0.2158.
AEs
North
America
significantly
higher
than
Europe,
being
0.0352
0.2622.
And
rates
prospective
0.0391
0.1771.
Retrospective
had
an
at
2.16,
0.2743.
Conclusion
This
found
there
certain
Immune
after
treatment
alemtuzumab.
Alemtuzumab
may
have
some
interference
levels,
mechanism
be
associated
Treg
cells.
But
due
absence
control
group
literature,
we
cannot
determine
specific
impact
on
MS.
Therefore,
clinical
physicians
should
perform
comprehensive
patient’s
benefit-to-risk
ratio
before
initiating
Systematic
Review
Registration
Inplasy
website,
DOI
number
is
10.37766/inplasy2024.3.0007
.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(18), С. 10262 - 10262
Опубликована: Сен. 6, 2022
Cladribine
(CLD)
treats
multiple
sclerosis
(MS)
by
selectively
and
transiently
depleting
B
T
cells
with
a
secondary
long-term
reconstruction
of
the
immune
system.
This
study
provides
evidence
CLD’s
immunomodulatory
role
in
peripheral
blood
mononuclear
(PBMCs)
harvested
from
40
patients
untreated
relapsing-remitting
MS
(RRMS)
exposed
to
CLD.
We
quantified
cytokine
secretion
PBMCs
isolated
density
gradient
centrifugation
Ficoll−Paque
using
xMAP
technology
on
FlexMap
3D
analyzer
highly
sensitive
multiplex
immunoassay
kit.
The
PBMC
secretory
profile
was
evaluated
without
CLD
exposure.
RRMS
for
≤12
months
had
significantly
higher
IL-4
but
lower
IFN-γ
TNF-α
after
>12
altered
inflammatory
ratios
toward
an
anti-inflammatory
increased
decreased
induced
nonsignificant
changes
IL-17
both
groups.
Our
findings
reaffirm
effect
that
induces
phenotype.
